The endothelium and atrial fibrillation

B. Freestone; G. Y. H. Lip

doi:10.1055/s-0037-1617102

Hämostaseologie, Table of Contents

Hamostaseologie 2008; 28(04): 207-212
DOI: 10.1055/s-0037-1617102

Original Article

Schattauer GmbH

The endothelium and atrial fibrillation

The prothrombotic state revisitedEndothel und VorhofflimmernProthrombotische Zustände neu betrachtet

B. Freestone

Haemostasis, Thrombosis, and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, United Kingdom

,

G. Y. H. Lip

Haemostasis, Thrombosis, and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, United Kingdom

› Author Affiliations

Abstract

Zusammenfassung

Vorhofflimmern (VHF), die häufigste anhaltende Herzrhythmusstörung, ist mit hohem Mortalitäts- und Morbiditätsrisiko verbunden. Es kann Schlaganfall und Thromboembolie verursachen. Mechanismen, die bei VHF Thromboembolie und nachfolgend zerebrovaskuläre Ereignisse auslösen, werden intensiv erforscht und müssen genau geklärt werden. VHF erfüllt zweifellos die Virchow-Trias der Thrombogenese: gestörte Blutzirkulation mit Verlust der Kontraktilität der Vorhöfe und absolute Kammerarrhythmie (d. h. gestörter Blutfluss), strukturelle Herzerkrankung mit Endothelschädigung (d. h. Gefäßwandläsionen), Abnormitäten bei Thrombozyten und hämostatischen Variablen (d. h. pathologische Blutbestandteile).

In dieser Übersicht werden die aktuellen Erkenntnisse zur Rolle der Blutgerinnung und fibrinolytischen Komponenten, Thrombozyten und Entzündungszellen (Blutzusammensetzung) zusammengefasst, die zu prothrombotischen Zuständen bei VHF führen. Dabei werden Endothel und VHF besonders berücksichtigt.

Summary

Atrial fibrillation (AF) is the commonest sustained cardiac arrhythmia, which confers a high risk of mortality and morbidity from stroke and thromboembolism. The precise mechanisms by which AF causes thromboembolism and subsequent cerebrovascular events have attracted much research interest, and are yet to be fully elucidated. Nonetheless, it is well recognised that AF fulfils Virchow’s triad for thrombogenesis, with abnormal flow conditions with loss of atrial contractility and an irregularly irregular cardiac output, (i. e. flow abnormalities), as well as structural heart disease with endocardial damage (i. e. abnormal vessel wall) and abnormalities in platelet and haemostatic variables (i. e. abnormal blood constituents).

This review is to summarise the evidence so far for the role of coagulation and fibrinolytic components, platelets and inflammation (that is blood constituents) in the generation of the prothrombotic state in AF, with particular focus on the endothelium and AF.

Schlüsselwörter

Vorhofflimmern - prothrombotischer Zustand - Endothelschädigung - Endotheldysfunktion

Keywords

Atrial fibrillation - prothrombotic state - endothelial damage - endothelial dysfunction

Full Text

References

References
1 Asakura H, Hifumi S, Jokaji H. et al. Prothrombin fragment F1+2 and thrombin-antithrombin III complex are useful markers of the hypercoagulable state in atrial fibrillation. Blood Coagul Fibrinolysis 1992; 3: 469-473.
2 Bulava A, Slavík L, Fiala M. et al. Endothelial damage and activation of the hemostatic system during radiofrequency catheter isolation of pulmonary veins. J Interv Card Electrophysiol 2004; 10: 271-279.
3 Choudhury A, Lip GY. Atrial fibrillation and the hypercoagulable state. Pathophysiol Haemost Thromb 2003; 33: 282-289.
4 Chung NA, Belgore F, Li-Saw-Hee FL. et al. Is the hypercoagulable state in atrial fibrillation mediated by vascular endothelial growth factor?. Stroke 2002; 33: 2187-2191.
5 Conway DS, Buggins P, Hughes E. et al. Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. J Am Coll Cardiol 2004; 43: 2075-2082.
6 Conway DS, Pearce LA, Chin BS. et al. Plasma von Willebrand factor and soluble p-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation. Circulation 2002; 106: 1962-1967.
7 Conway DS, Pearce LA, Chin BS. et al. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation 2003; 107: 3141-3145.
8 Corrado G, Beretta S, Sormani L. et al. Prevalence of atrial thrombi in patients with atrial fibrillation/ flutter and subtherapeutic anticoagulation prior to cardioversion. Eur J Echocardiogr 2004; 5: 257-261.
9 Corretti MC, Anderson TJ, Benjamin EJ. et al. International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endothelial- dependent flow-mediated vasodilation of the brachial artery. J Am Coll Cardiol 2002; 39: 257-265. Erratum: 1082.
10 de Denus S, Sanoski CA, Carlsson J. et al. Rate vs rhythm control in patients with atrial fibrillation: a metaanalysis. Arch Intern Med 2005; 165: 258-262.
11 Feinberg WM, Macy E, Cornell ES. et al. Plasminalpha2- antiplasmin complex in patients with atrial fibrillation. Thromb Haemost 1999; 82: 100-103.
12 Feinberg WM, Pearce LA, Hart RG. et al. Markers of thrombin and platelet activity in patients with atrial fibrillation. Stroke 1999; 30: 2547-2553.
13 Feng D, D’Agostino RB, Silbershatz H. et al. Hemostatic state and atrial fibrillation (the Framingham Offspring Study). Am J Cardiol 2001; 87: 168-171.
14 Freestone B, Chong AY, Nuttall S. et al. Impaired flow mediated dilatation as evidence of endothelial dysfunction in chronic atrial fibrillation. Thromb Res 2008; 122: 85-90.
15 Fukuchi M, Watanabe J, Kumagai K. et al. Increased von Willebrand factor in the endocardium as a local predisposing factor for thrombogenesis in overloaded human atrial appendage. J Am Coll Cardiol 2001; 37: 1436-1442.
16 Goldsmith I, Kumar P, Carter P. et al. Atrial endocardial changes in mitral valve disease. Am Heart J 2000; 140: 777-784.
17 Goldsmith IR, Foo LS, Blann AD. et al. Increased platelet activation and endothelial dysfunction in patients with atrial fibrillation immediately following percutaneous balloon mitral valvuloplasty. Clin Cardiol 2000; 23: 587-590.
18 Gustafsson C, Blombäck M, Britton M. et al. Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation. Stroke 1990; 21: 47-51.
19 Hagens VE, van Veldhuisen DJ, Kamp O. et al. RAte Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. Effect of rate and rhythm control on left ventricular function and cardiac dimensions in patients with persistent atrial fibrillation. Heart Rhythm 2005; 2: 19-24.
20 Hatzinikolaou-Kotsakou E, Kartasis Z. et al. Atrial fibrillation and hypercoagulability: dependent on clinical factors or/and on genetic alterations?. J Thromb Thrombol 2003; 16: 155-161.
21 Heppell RM, Berkin KE, McLenachan JM. et al. Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in non-rheumatic atrial fibrillation. Heart 1997; 77: 407-411.
22 Igarashi Y, Kasai H, Yamashita F. et al. Lipoprotein( a), left atrial appendage function and thromboembolic risk in patients with chronic nonvalvular atrial fibrillation. Jpn Circ J 2000; 64: 93-98.
23 Illien S, Maroto-Järvinen S, von der Recke G. et al. Atrial fibrillation: relation between clinical risk factors and transoesophageal echocardiographic risk factors for thromboembolism. Heart 2003; 89: 165-168.
24 Katoh H, Shimada T, Inoue S. et al. Reduced high serum hepatocyte growth factor levels after successful cardioversion in patients with atrial fibrillation. Clin Exp Pharmacol Physiol 2004; 31: 145-151.
25 Kumagai K, Fukunami M, Ohmori M. et al. Increased intracardiovascular clotting in patients with chronic atrial fibrillation. J Am Coll Cardiol 1990; 16: 377-380.
26 Kumagai K, Nakashima H, Saku K. The HMGCoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc Res 2004; 62: 105-111.
27 Leeuwenberg JF, Smeets EF, Neefjes JJ. et al. E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology 1992; 77: 543-549.
28 Leung DY, Black IW, Cranney GB. et al. Prognostic implications of left atrial spontaneous echo contrast in nonvalvular atrial fibrillation. J Am Coll Cardiol 1994; 24: 755-762.
29 Lip GY, Lowe GD, Rumley A. et al. Increased markers of thrombogenesis in chronic atrial fibrillation. Br Heart J 1995; 73: 527-533.
30 Lip GY. Does atrial fibrillation confer a hypercoagulable state?. Lancet 1995; 346: 1313-1314.
31 Lip GY, Rumley A, Dunn FG. et al. Plasma fibrinogen and fibrin D-dimer in patients with atrial fibrillation. Int J Cardiol 1995; 51: 245-251.
32 Li-Saw-Hee FL, Blann AD, Goldsmith I. et al. Indexes of hypercoagulability measured in peripheral blood reflect levels in intracardiac blood in patients with atrial fibrillation secondary to mitral stenosis. Am J Cardiol 1999; 83: 1206-1209.
33 Li-Saw-Hee FL, Blann AD, Gurney D. et al. Plasma von Willebrand factor, fibrinogen and soluble P-selectin levels in paroxysmal, persistent and permanent atrial fibrillation. Eur Heart J 2001; 22: 1741-1747.
34 Li-Saw-Hee FL, Blann AD, Lip GY. A cross-sectional and diurnal study of thrombogenesis among patients with chronic atrial fibrillation. J Am Coll Cardiol 2000; 35: 1926-1931.
35 Li-Saw-Hee FL, Blann AD, Lip GY. Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy, and dose-adjusted warfarin on thrombogenesis in chronic atrial fibrillation. Stroke 2000; 31: 828-833.
36 Marín F, Roldán V, Climent VE. et al. Plasma von Willebrand factor, soluble thrombomodulin, and fibrin D-dimer concentrations in acute onset nonrheumatic atrial fibrillation. Heart 2004; 90: 1162-1166.
37 Marín F, Roldán V, Lip GY. Fibrinolytic function and atrial fibrillation. Thromb Res 2003; 109: 233-240.
38 Minamino T, Kitakaze M, Sato H. et al. Plasma levels of nitrite/nitrate and platelet cGMP levels are decreased in patients with atrial fibrillation. Arterioscler Thromb Vasc Biol 1997; 17: 3191-3195.
39 Mitusch R, Siemens HJ, Garbe M. et al. Detection of a hypercoagulable state in nonvalvular atrial fibrillation and the effect of anticoagulant therapy. Thromb Haemost 1996; 75: 219-223.
40 Mondillo S, Sabatini L, Agricola E. et al. Correlation between left atrial size, prothrombotic state and markers of endothelial dysfunction in patients with lone chronic nonrheumatic atrial fibrillation. Int J Cardiol 2000; 75: 227-232.
41 Nakamura Y, Nakamura K, Fukushima-Kusano K. et al. Tissue factor expression in atrial endothelia associated with nonvalvular atrial fibrillation. Thromb Res 2003; 111: 137-142.
42 Nikitovic D, Zacharis EA, Manios EG. et al. Plasma levels of nitrites/nitrates in patients with chronic atrial fibrillation are increased after electrical restoration of sinus rhythm. J Interv Card Electrophysiol 2002; 7: 171-176.
43 Nishino M, Hoshida S, Tanouchi J. et al. Time to recover from atrial hormonal, mechanical, and electrical dysfunction after successful electrical cardioversion of persistent atrial fibrillation. Am J Cardiol 2000; 85: 1451-1454.
44 Opolski G, Torbicki A, Kosior DA. et al. Investigators of the Polish How to Treat Chronic Atrial Fibrillation Study. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest 2004; 126: 476-486.
45 Roldán V, Marín F, Lip GY. et al. Soluble E-selectin in cardiovascular disease and its risk factors. A review of the literature. Thromb Haemost 2003; 90: 1007-1020.
46 Roldán V, Marín F, Marco P. et al. Hypofibrinolysis in atrial fibrillation. Am Heart J 1998; 136: 956-960.
47 Soncini M, Casazza F, Mattioli R. et al. Hypercoagulability and chronic atrial fibrillation: the role of markers of thrombin generation. Minerva Med 1997; 88: 501-505.
48 Stoddard MF, Dawkins PR, Prince CR. et al. Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardiographic study. J Am Coll Cardiol 1995; 25: 452-459.
49 Sulke N, Sayers F, Lip GY. Guideline Development Group for the NICE clinical guideline for the management of atrial fibrillation. Rhythm control and cardioversion. Heart 2007; 93: 29-34.
50 Takahashi N, Ishibashi Y, Shimada T. et al. Impaired exercise-induced vasodilatation in chronic atrial fibrillation--role of endothelium-derived nitric oxide. Circ J 2002; 66: 583-588.
51 Takahashi N, Ishibashi Y, Shimada T. et al. Atrial fibrillation impairs endothelial function of forearm vessels in humans. J Card Fail 2001; 7: 45-54.
52 Vene N, Mavri A, Kosmelj K. et al. High D-dimer levels predict cardiovascular events in patients with chronic atrial fibrillation during oral anticoagulant therapy. Thromb Haemost 2003; 90: 1163-1172.
53 Yamamoto K, Ikeda U, Seino Y. et al. Coagulation activity is increased in the left atrium of patients with mitral stenosis. J Am Coll Cardiol 1995; 25: 107-112.